Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. grew its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 14.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 111,478 shares of the life sciences company's stock after acquiring an additional 14,436 shares during the period. Asset Management One Co. Ltd. owned about 0.07% of Illumina worth $8,845,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. State of Alaska Department of Revenue boosted its position in shares of Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock worth $1,469,000 after buying an additional 445 shares during the period. Raymond James Financial Inc. acquired a new position in Illumina during the 4th quarter worth about $50,577,000. Merit Financial Group LLC boosted its holdings in Illumina by 344.8% during the 1st quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after acquiring an additional 10,105 shares during the period. Trexquant Investment LP grew its position in Illumina by 16.7% in the 4th quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company's stock valued at $19,106,000 after acquiring an additional 20,506 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. increased its stake in Illumina by 699.3% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 17,217 shares of the life sciences company's stock worth $2,301,000 after purchasing an additional 15,063 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction dated Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Illumina Stock Performance

NASDAQ:ILMN traded up $0.63 during mid-day trading on Friday, reaching $94.79. 3,837,289 shares of the stock were exchanged, compared to its average volume of 2,142,698. The stock has a market capitalization of $15.01 billion, a P/E ratio of -15.62, a P/E/G ratio of 1.86 and a beta of 1.32. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a 50 day simple moving average of $82.69 and a 200-day simple moving average of $98.98. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the firm posted $0.98 earnings per share. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several analyst reports. Citigroup lowered their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Morgan Stanley lowered their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Canaccord Genuity Group lifted their price target on shares of Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.